In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...
The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for ...
AMD's next CPU launch is going to be the Gorgon Point family. Don't wet yourself in excitement; they're primarily refreshed ...
In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets presented at the American Academy of Ophthalmology meeting.Eichenbaum noted that ...
EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On November 19, 2025, EyePoint Pharmaceuticals announced a positive ...
No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...
Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.
New moms are inundated with information about feeding their babies. There’s breastfeeding, there’s pumping, there’s formula, ...
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) from Outlook Therapeutics for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback